Adipiplon (NG2-73) is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.
Adipiplon is a subtype selective GABAA partial agonist, which binds preferentially to the ?3 subtype. This is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for ?2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which is able to discriminate between ?2 and ?3, as well as showing little affinity for the ?1 or ?5 subtypes - alpidem is selective for ?3 over ?2, but still has moderate affinity to ?1, whereas adipiplon is highly ?3-selective with little affinity for either ?1, ?2 or ?5.
Adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and is currently (as of 200 in Phase IIb trials
CGS-9896 is an anxiolytic drug used in scientific research.
It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.
CGS-9896 is a benzodiazepine receptor partial agonist, which produces long-lasting anxiolytic and anticonvulsant effects in animal studies, but does not produce sedative effects
. It also increases appetite, and reduces the development of gastrointestinal ulcers following chronic stress.
CGS-20625 is an anxiolytic drug used in scientific research.
It has similar effects to, and binds to the same target as benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.
CGS-20625 produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses
, and no significant muscle relaxant effects. It is orally active in humans, but with relatively low bioavailability.
Etifoxine (or etafenoxine) is an anxiolytic and anticonvulsant drug. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It is more effective than lorazepam as an anxiolytic, but has less side effects
Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to ?2 and ?3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines. This difference in binding means that etifoxine can be used alongside benzodiazepines to potentiate their effects without competing for binding sites, however it also means that the effects of etifoxine are not reversed by the benzodiazepine antagonist flumazenil.
Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.
Pagoclone was originally developed as an anti-anxiety drug, but never commercialised. It is a partial agonist acting at GABAA receptors in the brain. In contrast to zopiclone, pagoclone produces anxiolytic effects with little or no sedative or amnestic actions at low doses
I wish I could fast forward time about 10 years, without aging.